Table 2.

AuNP-based formulations approved for clinical trials by FDA. Adapted from [19, 32]

AuNP formulation	Condition or disease	Properties of the metallic NPs	NCT number
Aurrimune	Late stage pancreatic, breast, colon, melanoma, sarcoma and lung cancer	27 nm AuNPs core loaded with TNF-α and PEG	NCT00356980 NCT00436410
Aurolase	Refractory and/or recurrent tumors for head and neck cancer Primary and/or metastatic lung tumors	150 nm silica-gold nanoshells coated with PEG	NCT00848042 NCT01679470
Sebacia Microparticles	Acne vulgaris	150 nm silica-gold nanoshells coated with PEG	NCT02219074 NCT02217228
C19-A3 GNP peptide	Type 1 diabetes	AuNPs with peptide fragment related to insulin	NCT02837094
NU-0129	Gliosarcoma
Recurrent glioblastoma	AuNPs with nucleic acid	NCT03020017
NANOM-FIM	Stable angina Heart failure Atherosclerosis
Multivessel coronary artery disease	Silica- AuNPs vs AuNPs with silica–iron oxide shells with photothermic burning or melting effect onto the lesion	NCT01270139
Nano Care Gold	Cavity pre-treatment in Caries class Ii	AgNPs and AuNPs in 70% isopropyl alcohol	NCT03669224
Exhaled Breath Olfactory Signature (Artificial Nose)	Pulmonary hypertension	AuNPs coated with organic ligands as sensor array for detection of volatile organic compounds in breath of patients	NCT02782026
Na-nose	Gastric diseases	Functionalized AuNPs and carbon nanotubes nanosensor arrays	NCT01420588
Nanomedical Artificial Olfactory System	Parkinson’s disease Parkinsonism	Functionalized AuNPs and carbon nanotubes nanosensor arrays	NCT01246336